Clinical Report: Evaluating the Efficacy of Long-Acting Injectable Buprenorphine

Overview

This case study highlights the delayed withdrawal symptoms experienced by a patient four months after a single dose of long-acting injectable buprenorphine (Sublocade).

Background

Long-acting injectable buprenorphine (LAIB) has emerged as a potential strategy for tapering patients off buprenorphine therapy. This case illustrates the complexities of tapering and the potential for delayed withdrawal symptoms.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• A 45-year-old man developed withdrawal symptoms four months after a single 200 mg dose of LAIB (Sublocade).
• Withdrawal symptoms included GI upset, fatigue, malaise, and mood-related issues.
• Administration of naltrexone worsened withdrawal symptoms.
• Transdermal buprenorphine was effective in attenuating withdrawal symptoms.
• Loss of kappa opioid receptor antagonism may contribute to atypical withdrawal symptoms.

Clinical Implications

Clinicians should be aware of the potential for delayed withdrawal symptoms when tapering patients using LAIB.

Conclusion

This case highlights the delayed withdrawal symptoms in a patient tapering off buprenorphine using LAIB.

Related Resources & Content

1. JAMA Internal Medicine, 2026 -- Extended-Release vs Sublingual Buprenorphine in Pregnancy Through 12 Months Post Partum: A Randomized Clinical
2. JAMA Network Open, 2026 -- Adjunctive Psychosocial Interventions and Opioid Abstinence Among Patients Receiving Buprenorphine
3. JAMA Internal Medicine, 2026 -- Error in Conclusions
4. WHO, 2026 -- WHO updates guidelines on opioid dependence treatment and overdose prevention
5. SAMHSA, 2025 -- Medications for Opioid Use Disorder
6. JAMA Network Open — High-Deductible Health Plan Enrollment and Buprenorphine Dispensing
7. FDA Label for Sublocade
8. WHO updates guidelines on opioid dependence treatment and overdose prevention
9. Medications for Opioid Use Disorder | SAMHSA
10. Rapid vs Standard Induction to Injectable Extended-Release Buprenorphine: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA Network Open | JAMA Network
11. Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use: A Randomized Clinical Trial - PubMed
12. Characterizing withdrawal from long-acting injectable buprenorphine: An observational case series - ScienceDirect